Send to

Choose Destination
Glob Pediatr Health. 2016 Jul 4;3:2333794X16654851. doi: 10.1177/2333794X16654851. eCollection 2016.

The Effectiveness and Safety of a Homeopathic Medicinal Product in Pediatric Upper Respiratory Tract Infections With Fever: A Randomized Controlled Trial.

Author information

International Institute for Integrated Medicine, Kingston, UK.
General Practitioner, Private Practice, Munich, Germany.
Bogomolets National Medical University, Kiev, Ukraine.
International Health Center of the Hague, The Hague, The Netherlands.
Acomed statistik, Leipzig, Germany.
Deutsche Homöopathie-Union, Karlsruhe, Germany.


We investigated the clinical effectiveness of a homeopathic add-on therapy in a pediatric subpopulation with upper respiratory tract infections (URTI) in a randomized, controlled, multinational clinical trial. Patients received either on-demand symptomatic standard treatment (ST-group) or the same ST plus a homeopathic medication (Influcid; IFC-group) for 7 days. Outcome assessment was based on symptom and fever resolution and the Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-21). A total of 261 pediatric (<12 years) patients (130 IFC-group; 131 ST-group) were recruited in Germany and the Ukraine. The IFC-group used less symptomatic medication, symptoms resolved significantly earlier (P = .0001), had higher proportions of fever-free children from day 3 onwards, and the WURSS-assessed global disease severity was significantly less (P < .0001) during the entire URTI episode. One adverse event (vomiting) was possibly related to IFC. IFC as add-on treatment in pediatric URTI reduced global disease severity, shortened symptom resolution, and was safe in use.


Influcid®; fever; homeopathy; pediatrics; randomized controlled clinical trial; upper respiratory tract infections

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center